Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIN2B | Q13224 | 3/20 | 0.51 |
| ▸ | FUCA1 | P04066 | 2/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.49 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.47 |
| ▸ | DRD2 | P14416 | 1/20 | 0.47 |
| ▸ | DRD3 | P35462 | 1/20 | 0.47 |
| ▸ | ACHE | P22303 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5242542 | 0.85 | FUCA1 (0.64) | GRIN2BFUCA1HRH3SIGMAR1DRD2 | |
| SCHEMBL9269370 | 0.83 | KMT2A (0.48) | FUCA1KDM4EMEN1KMT2AHRH3 | |
| SCHEMBL9265205 | 0.82 | TACR1 (0.47) | FUCA1KDM4EMEN1KMT2AHRH3 | |
| SCHEMBL13326662 | 0.81 | GRIN2B (0.47) | GRIN2BFUCA1KDM4EMEN1KMT2A | |
| SCHEMBL1796837 | 0.80 | MC4R (0.58) | GRIN2BFUCA1HRH3SIGMAR1DRD2 | |
| SCHEMBL21064724 | 0.80 | FUCA1 (0.55) | GRIN2BFUCA1HRH3SIGMAR1DRD2 | |
| SCHEMBL16837173 | 0.80 | FUCA1 (0.58) | GRIN2BFUCA1SIGMAR1DRD2DRD3 | |
| SCHEMBL13326688 | 0.78 | GRIN2B (0.50) | GRIN2B | |
| SCHEMBL12372536 | 0.77 | FUCA1 (0.60) | GRIN2BFUCA1SIGMAR1DRD2DRD3 | |
| SCHEMBL13783796 | 0.77 | FUCA1 (0.60) | GRIN2BFUCA1SIGMAR1DRD2DRD3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10308614-B2 | Therapeutic compounds and uses thereof | GENENTECH, INC. (US) | 2019-06-04 | — | — | US | disclosed |
| US-20180086720-A1 | THERAPEUTIC COMPOUNDS AND USES THEREOF | GENENTECH, INC. (US) | 2018-03-29 | — | — | US | disclosed |
| US-20180086720-A1 | THERAPEUTIC COMPOUNDS AND USES THEREOF | GENENTECH, INC. (US) | 2018-03-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10308614-B2 | Therapeutic compounds and uses thereof | SMARCC1, SMARCC2, SMARCA4 | GRIN2B 1577/4885FUCA1 3575/4885KDM4E 1623/4885 |
| US-20180086720-A1 | THERAPEUTIC COMPOUNDS AND USES THEREOF | SMARCC1, SMARCC2, SMARCA4 | GRIN2B 1577/4885FUCA1 3575/4885KDM4E 1623/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.